Danaher
✦ Quant Fair Value how this is computed
- Implied fair-value range of 147.20-218.73, from this stock's own trailing 5-year average P/E applied to trailing EPS.
- Current price is +20.4% above the average-multiple fair value of 182.97.
Valuation each multiple against its own 5-year range
Vs. peers Diagnostics & Research
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Danaher (DHR) | 155.03B | 36.12 | 2.89 | 0.69% |
| Thermo Fisher Scientific (TMO) | 248.08B | 35.31 | 4.53 | 0.27% |
| IDEXX Laboratories Inc (IDXX) | 53.28B | 45.57 | 28.50 | 0.00% |
| Agilent Technologies (A) | 48.04B | 33.61 | 6.52 | 0.59% |
| Waters (WAT) | 43.29B | 184.29 | 2.83 | 0.00% |
| IQVIA Holdings (IQV) | 40.51B | 29.91 | 6.08 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 12.1% below Morningstar's fair value estimate.
Analyst note
On Oct. 20, Danaher reported third-quarter results that included 3% core revenue growth, at the top end of its previous 2%-3% outlook, and adjusted EPS growth of 12% to $2.11, well above the consensus of $1.92. Management also increased its 2026 EPS guidance to $8.57-$8.62 from $8.45-$8.60.
Why it matters: In early trading, Danaher shares rose about 3%, reflecting the higher-than-anticipated 2026 profit outlook, including strong margin performance and solid core revenue growth trends. Specifically, the quarter's 3% core revenue growth was held back by ongoing headwinds in respiratory, but strong mid-single-digit sales growth and mid-teens order growth in bioprocessing suggest that important business could return to its targeted high-single-digit growth rate in the near future. For 2027, management gave a starting point for core revenue growth excluding respiratory of 4%-5% on the call, which appears similar to the mid-single-digit core revenue growth expectation for 2026 and similar to our 2027 expectation excluding recent acquisitions like Masimo.
The bottom line: A mild boost to our 2026 profit view does not change our $247 fair value estimate for wide-moat Danaher. We expect Danaher's shares to remain near fair value after this news and the share movement. Going forward, core revenue and profit growth could accelerate through 2030 on trends like reshoring by drug manufacturers (likely a 2028+ event according to management), refreshing instruments purchased during the pandemic boom, and potential artificial intelligence-related demand and cost-control efforts. Danaher also remains one of our favorite companies in life sciences and diagnostics with a wide moat stemming from intangible assets—like patents, copyrights, and trademarks—in differentiated technology and substantial customer switching costs associated with its tools.
BLANK PAGEFor more details on the life science industry's recent history and potential profit growth catalysts in one of the moatiest parts of this industry where Danaher operates, please see our March research, “After a Long Reset Period, Life Science Stocks Look Set to Rebound."
Fair value
We are reducing our fair value estimate on Danaher by 9% to $247 per share from $270 mainly on slightly weaker near-term assumptions for the biotechnology segment after a few large customers pushed back shipments to 2027 due to production schedule changes and site readiness issues combined with subdued cash flow estimates related to weaker working capital assumptions.
Over the long run, though, we expect growth to accelerate to more normal levels. Specifically, we see potential positive catalysts in the 2027-30 timeframe, as demand for its life science tools rises with expected biopharmaceutical reshoring efforts and as pandemic-era instruments reach the end of their lifespans and need to be refreshed. Artificial intelligence-related demand and cost-control efforts could boost profit opportunities, as well. From a trend perspective, those potential profit catalysts have increased five-year forecast assumptions above typical norms but will be offset by another reset period after 2030.
Through 2035, our fair value estimate depends on 6% top-line growth and 8% free cash flow growth, compounded annually, which we think appropriately reflects the prospects of Danaher's end markets on the top line and its continuous-improvement prowess on the bottom line. Also, while we suspect management will try to deliver double-digit earnings growth over the next 10 years, our model excludes any unannounced acquisitions or share repurchases, which would likely be required to do so, in our view.
Economic moat
We believe a wide moat surrounds Danaher’s diversified set of businesses, and we see intangible assets and switching costs as its moat sources. Investors should note that Danaher’s merger, acquisition, and divestiture activities may keep its economic profit margins quite slim when including goodwill. However, our wide moat rating recognizes the attractive fundamental qualities of Danaher's current businesses, which we expect will help the company deliver long-term economic profitability and the potential for continuous improvement of acquired businesses through the Danaher Business System.
Intangible Assets
Danaher offers differentiated technology that is protected by various intangible assets, including patents, brands, copyrights, and trademarks. Those intangible assets prevent identical copycats for a long period of time. Since even slightly differentiated technical features can cause an end user to prefer one tool over another in Danaher's precise scientific end markets, we see intangible assets around its differentiated technology and its ability to innovate in its target markets.
Switching Costs
Also, once its products are chosen due to their differentiated features for a specific application, Danaher is often able to layer on substantial switching costs for customers. Danaher's tools enable the essential operations of its clients, and switching to a competitor's technology could change the outcome of those operations, which would be undesirable for users once Danaher’s products are incorporated into their workflow. About 80% of Danaher’s revenue streams are recurring in nature, and most of those sales are considered captive, meaning customers cannot use another supplier if it wants to keep using Danaher’s instruments or equipment. That dynamic highlights the razor/razor blade model that Danaher pursues with its differentiated technology. However, the durability of Danaher’s competitive advantages differs by product set.
Biotechnology
Within its biotechnology segment (nearly 40% of 2025 profits), we believe Danaher has dug a wide moat with particularly long revenue streams related to durable switching costs for customers along with intangible assets. The differentiated properties of Danaher's tools affect the performance, accuracy, and speed of the various research projects they enable, and those product features create intangible assets that inform decisions to use those tools in specific applications at the beginning of a research project. After those initial decisions are made, we see a particularly sticky business in its tools to help biopharmaceutical clients manufacture drug therapies. Once Danaher’s products are chosen as part of the production process of a molecule near the beginning of the clinical trial process, the client appears unlikely to switch suppliers for that tool due to regulatory and reproducibility factors. Additionally, if that molecule is successfully marketed, the revenue stream would likely continue through the product’s life cycle. From discovery to patent expiration, Danaher could generate recurring revenue for at least 20 years on a molecule in the branded phase and even longer if generic or biosimilar manufacturers choose to use the same manufacturing process beyond a drug’s patent expiration. That long durability of these revenue streams gives us confidence that this segment has a wide moat around it.
Life Sciences
In its life sciences segment (about 10% of 2025 profits), we see a narrower moat than in biotechnology because they are typically used in shorter-duration projects. However, concerns about reproducibility in the customers’ test results during the course of a research project can create some inertia to switch from this segment’s technologies, and there are recurring revenue for the life of its equipment in this narrower moat segment, as well. However, the company also sells some building blocks of cell and gene therapies in this segment. As cell and gene therapies become more prevalent, Danaher could eventually enjoy more durable switching costs in this segment because those products would be spec’d into each therapy’s manufacturing process, similar to the highly durable switching costs in the biotechnology segment discussed above.
Diagnostics
In diagnostics (about half of 2025 profits), Danaher provides a broad set of tools—including clinical chemistry, immunoassays, hematology, tissue-based, and molecular diagnostics—which it sells primarily to hospitals, physician offices, and reference labs for use on patients’ blood, urine, or tissue samples. Economic moats in this business are typically derived from a mix of intangible assets and switching costs. Getting a diagnostic system placed in a lab initially relates to the differentiated features of Danaher’s proprietary technology, which contributes to the intangible assets moat source of this segment. However, once placed and in regular use, we see some switching costs in Danaher’s diagnostic tools, too, although shorter in durability than its other segments. Specifically, displacing an established diagnostic platform can be challenging for competitors since labs are hesitant to replace systems that are integrated into their workflows. So even when a test is relatively simple scientifically, customers often show loyalty to tools that make their workflows easier, creating an inertia-related switching cost for incumbent players like Danaher in this end market.
Bull case
The Danaher Business System focuses on continuous improvement, including the acceleration of core growth and margin expansion through marketing initiatives and innovation, which appears positive for Danaher's long-term prospects.
Danaher’s shift to healthcare markets has created a less cyclical business in attractive markets with high barriers to entry and impressive recurring consumables revenue streams.
Danaher has plenty of opportunities to consolidate and improve performance in its targeted life sciences and diagnostic end markets.
Bear case
Danaher continues to hunt for acquisitions in the life sciences and diagnostics markets, which could constrain ROICs including goodwill if it makes acquisitions at unattractive prices and is not able to integrate them as successfully as in the past.
Danaher faces significant competition in its target niches and must remain dedicated to ongoing innovation to remain relevant, which is not guaranteed.
The postpandemic reset period has proved challenging for growth rates in Danaher's target markets and may remain so, judging by 2026 guidance.
By Julie Utterback, CFA
Quote time 2026-11-20 20:02:24 · For reference only, not investment advice and not tailored to your situation.
Danaher discussion 0 comments